This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

BAX 817

Shire Pharmaceuticals Group PLC

Drug Names(s): Recombinant Factor VIIa, rFVIIa

Description: BAX 817 is a recombinant factor VIIa therapy. Factor VII is a serine protease involved in the initiation of the coagulation cascade in conjunction with tissue factor (TF). Upon binding of TF, factor VII is activated to factor VIIa by various proteases. Substrates of factor VIIa-TF include factor X and factor IX.

Deal Structure: Baxter and Baxalta
In March 2014, Baxter announced plans to create two separate, independent global healthcare companies one focused on developing and marketing biopharmaceuticals (Baxalta Incorporated) and the other on medical products. In July 2015, Baxalta Incorporated launched as a stand-alone biopharmaceutical company.

Shire and Baxalta
In January 2016, Shire and Baxalta announced that the boards of directors of both companies have reached an agreement under which Shire will combine with Baxalta. Under the agreement, Baxalta shareholders will receive $18.00 in cash and 0.1482 Shire ADS per Baxalta share. Based on Shire's closing ADS price on January 8, 2016, this implies a total current value of $45.57 per Baxalta share, representing an aggregate consideration of approximately $32 billion. The exchange ratio is based on Shire's 30-day trading day volume weighted average ADS price of $199.03 as of January 8, 2016, which implies a total value of...See full deal structure in Biomedtracker

BAX 817 News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug